- Severity decides site of care: PSI or CURB-65 + judgment; IDSA/ATS severe criteria for ICU.
- Non-severe inpatient: ceftriaxone + azithromycin (or doxycycline), or a respiratory fluoroquinolone alone.
- Cover MRSA/Pseudomonas only if prior isolate — or recent hospitalization + IV antibiotics and local risk. Get cultures + nasal MRSA PCR and de-escalate.
- Severe CAP → add hydrocortisone (ATS 2025). No steroids for non-severe CAP.
- Short courses: stable by day 3 → 3–5 days total is enough for non-severe CAP. Longer for severe, S. aureus, Pseudomonas, empyema.
Pathophysiology in 60 seconds
⌄
- Micro-aspiration of oropharyngeal flora (or inhaled droplets) beats the lung's defenses → alveolar inflammation → exudate fills alveoli → V/Q mismatch and shunt → hypoxemia.
- Common bugs: S. pneumoniae, H. influenzae, M. catarrhalis, atypicals (Mycoplasma, Chlamydophila, Legionella), viruses (influenza, RSV, SARS-CoV-2, hMPV). S. aureus after influenza.
Diagnosis
⌄
- New infiltrate + symptoms (fever, cough, dyspnea, pleuritic pain, crackles).
- Lung ultrasound is an acceptable alternative to CXR where expertise exists (ATS 2025).
- Inpatients: blood cultures + sputum culture if severe or MRSA/PsA risk; Legionella + pneumococcal urine antigens if severe; respiratory viral PCR; nasal MRSA PCR if MRSA coverage started.
- Procalcitonin: does not decide whether to start antibiotics.
| CURB-65 (1 each) | |
|---|---|
| Confusion | |
| Urea >19 mg/dL (BUN >7 mmol/L) | |
| RR ≥30 | |
| BP SBP <90 or DBP ≤60 | |
| Age ≥65 | |
| 0–1 home · 2 admit · ≥3 consider ICU |
Severe CAP (IDSA/ATS): 1 major (septic shock on pressors, or mechanical ventilation) or ≥3 minor (RR ≥30, P/F ≤250, multilobar, confusion, BUN ≥20, WBC <4 k, platelets <100 k, T <36 °C, hypotension needing fluids).
Management
⌄
| Setting | Regimen |
|---|---|
| Ward, non-severe | Ceftriaxone 1–2 g daily + azithromycin 500 mg daily (or doxycycline 100 mg BID) · or levofloxacin 750 mg / moxifloxacin 400 mg |
| Severe / ICU | β-lactam + azithromycin (preferred) or + respiratory FQ |
| Prior MRSA (resp) | Add vancomycin or linezolid → stop if nasal PCR & cultures negative |
| Prior Pseudomonas (resp) | Cefepime / pip-tazo / meropenem |
| Aspiration | No routine anaerobic coverage unless abscess or empyema |
| Influenza positive | Oseltamivir too |
- Severe CAP: hydrocortisone 200 mg/day (e.g., 50 mg IV q6h or infusion) for 4–7 days, taper by response (CAPE COD regimen).
- Non-severe CAP: do not give systemic steroids (strong recommendation).
- Avoid in influenza pneumonia; caution in aspergillosis risk.
- Switch to PO when improving, afebrile, eating, hemodynamically stable.
- Non-severe, clinically stable by day 3 → minimum 3 days; ~5 days total is acceptable.
- Severe CAP, MRSA, Pseudomonas, empyema, abscess → individualize (≥7 days).
- Positive viral test, hospitalized → ATS 2025 suggests still giving antibacterial therapy (co-infection is hard to exclude); reassess early and stop if the bacterial workup is negative and the patient improves. Outpatients with a virus and no major comorbidity can often skip antibiotics.
Pitfalls
⌄
- Reflex "HCAP" vancomycin + pip-tazo (HCAP no longer exists).
- Missing empyema in a slow responder → ultrasound/CT, tap.
- 10–14 day courses "to be safe."
- Not checking QTc with azithro/FQ combos.
Board corner
⌄
| Stem | Answer |
|---|---|
| CAP, ward, no MRSA/PsA risk | Ceftriaxone + azithromycin |
| Severe CAP on pressors | β-lactam + macrolide + hydrocortisone |
| Necrotizing pneumonia after influenza | S. aureus (MRSA) → vancomycin/linezolid |
| Hyponatremia, diarrhea, high fever, confusion | Legionella → urine antigen, azithro/levofloxacin |
| Still febrile day 4, dull base | Parapneumonic effusion → tap |
References
⌄
- Jones BE, Ramirez JA, et al. Diagnosis and Management of CAP. ATS Clinical Practice Guideline. AJRCCM. 2025 (endorsed by ATS).
- Metlay JP, et al. 2019 ATS/IDSA CAP guideline. AJRCCM. 2019;200:e45.
- Dequin PF, et al. CAPE COD. NEJM. 2023;388:1931.